Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments

INTRODUCTION: Patients with cancer (PC) are at high risk of acquiring COVID-19 and can develop more serious complications. Deeper understanding of vaccines immunogenicity in this population is crucial for adequately planning vaccines programs. The ONCOVac study aimed to comprehensively assess the im...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortés, Alfonso, Casado, José L., Longo, Federico, Serrano, Juan J., Saavedra, Cristina, Velasco, Héctor, Martin, Adrián, Chamorro, Jesús, Rosero, Diana, Fernández, María, Gion, María, Martínez Jáñez, Noelia, Soria Rivas, Ainara, Alonso Gordoa, Teresa, Martínez Delfrade, Íñigo, Lage, Yolanda, López Miranda, Elena, Olmedo, María E., Reguera Puertas, Pablo, Gajate, Pablo, Molina Cerrillo, Javier, Guerra Alia, Eva, Fuentes Mateos, Raquel, Romero, Beatriz, Rodríguez-Domínguez, Mario J., Vallejo, Alejandro, Carrato, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885286/
https://www.ncbi.nlm.nih.gov/pubmed/35316750
http://dx.doi.org/10.1016/j.ejca.2022.02.017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885286/
https://www.ncbi.nlm.nih.gov/pubmed/35316750
http://dx.doi.org/10.1016/j.ejca.2022.02.017

Ejemplares similares